China Insulin Delivery Devices Market Overview, 2031

China has a large and growing population, and the prevalence of diabetes has been increasing. The expanding middle class in China has resulted in increased awareness about healthcare and a greater ability to afford medical treatments. This has contributed to the growth in demand for advanced healthcare solutions, including insulin delivery devices. Urbanization often leads to changes in lifestyle, including dietary habits and physical activity levels. These changes can contribute to an increase in the prevalence of diabetes, driving the demand for insulin delivery devices. The Chinese government has been actively working on improving healthcare infrastructure and increasing healthcare spending. This includes investments in diabetes management and treatment, leading to a higher adoption of insulin delivery devices. China has been actively investing in research and development R&D across various industries, including healthcare. This commitment to technological advancement has likely led to the development of innovative insulin delivery devices, attracting both healthcare professionals and patients to adopt these newer and more efficient technologies. Type 2 diabetes is the more common form of diabetes, often associated with lifestyle factors. Given the changing lifestyle patterns in China, including dietary habits and sedentary lifestyles in urban areas, the prevalence of type 2 diabetes is on the rise. This, in turn, increases the demand for insulin delivery devices. China's rapid economic growth has resulted in an improvement in the standard of living and an increase in disposable income. This economic prosperity enables more individuals to afford advanced healthcare solutions, including insulin delivery devices.

According to the research report, " China Insulin Delivery Devices Market Overview, 2031," published by Bonafide Research, the China Insulin Delivery Devices market is anticipated to grow at more than 7.61% CAGR from 2026 to 2031. The prevalence of diabetes in China has been on the rise, driven by factors such as changing lifestyles, dietary habits, and an aging population. This has led to an increased demand for insulin delivery devices as part of diabetes management. The adoption of smart insulin delivery devices, which include features like connectivity to mobile apps for data tracking and remote monitoring, has been a notable trend. These devices offer patients and healthcare providers real-time insights into diabetes management. Efforts have been made to make insulin and insulin delivery devices more affordable and accessible to a broader population. This includes initiatives to reduce the cost of these devices and increase their availability in both urban and rural areas. The integration of AI and big data analytics in healthcare has the potential to enhance diabetes management. In the context of insulin delivery devices, AI algorithms can analyze patient data to provide personalized recommendations, improving treatment outcomes. CGM devices provide real-time glucose monitoring, offering a more comprehensive view of a patient's blood glucose levels. The integration of CGM technology with insulin delivery devices allows for more precise insulin administration, reducing the risk of hypoglycemia. As awareness of diabetes in children grows, there may be an increased focus on developing insulin delivery devices specifically designed for pediatric use. Child-friendly designs and features may become more prevalent in the market.

China insulin delivery devices market by product types is divided into insulin pens, insulin pump, insulin syringes and other insulin delivery services. In China, the market for insulin delivery devices is organized into insulin pens, insulin pumps, insulin syringes, and al devices for insulin delivery, indicating a shift towards contemporary methods of diabetes management in the country. Currently, insulin pens lead the market in revenue and unit sales due to their user-friendliness, convenience, accurate dosing, and preference among patients, particularly those with Type 2 diabetes. The large number of diabetics in China, along with the growing acceptance of organized diabetes care programs, has led to a significant rise in the use of both disposable and reusable insulin pens, with expectations for continued growth as patient knowledge improves. Recent market findings suggest that insulin pens generated the most revenue in China's insulin delivery market in 2023 and are anticipated to retain a substantial market share until 2030. Insulin pumps represent the fastest expanding category in China, spurred by advancements in technology and an increase in usage among patients who need intensive insulin treatment, especially those with Type 1 diabetes. Innovative systems like hybrid closed-loop pumps that combine continuous glucose monitoring CGM are being introduced to the Chinese market following endorsement from regulators and aim to enhance blood sugar control while easing the burden on patients. These advancements, bolstered by national healthcare education and reimbursement initiatives, are promoting device adoption in urban areas and specialized clinics. Insulin syringes, although traditionally significant and still in use in some clinical and emergency care environments, hold a smaller market share in comparison as patients and healthcare providers are moving toward more modern and user-friendly options.

China insulin delivery devices market by disease types is divided into type 1 and type 2. The landscape of the insulin delivery devices market in China is greatly shaped by the high incidence of diabetes within the population, creating distinct demand patterns between Type 1 and Type 2 diabetes. China hosts one of the largest diabetes patient populations ly, influenced by rapid urban development, changes in lifestyle, an aging population, and eating habits, which have collectively heightened the challenge of Type 2 diabetes. Consequently, patients with Type 2 diabetes represent the overwhelming majority of users of insulin delivery devices in China, predominantly fueling the demand for insulin pens. These pens are particularly advantageous for this extensive patient group as they simplify the process of administering insulin, improve dosing precision, and promote adherence to treatment in outpatient and home care contexts. Their availability through hospital pharmacies, retail outlets, and online health services further boosts their acceptance. In comparison, Type 1 diabetes constitutes a lesser portion of the diabetic demographic; however, it is a crucial segment for sophisticated delivery devices due to the ongoing reliance on insulin therapy and the necessity for strict glycemic management. Individuals diagnosed with Type 1 diabetes are progressively using insulin pumps, which facilitate continuous subcutaneous insulin delivery CSII and, when paired with CGM systems, can greatly enhance glucose control and well-being. The approval of hybrid closed-loop systems by regulators and growing clinical expertise with pump usage in top endocrinology centers are further promoting the adoption of these advanced devices within the Type 1 community.

China insulin delivery devices market by end user is divided into home care setting, hospitals and clinics and other end users. From the perspective of end users, the market for insulin delivery devices in China is divided into home care settings, hospitals & clinics, and other end users like community health services, long-term care facilities, and specialized diabetes centers. Historically, hospitals and clinics have maintained a large share of device usage due to their role in diagnosing diabetes, starting insulin therapy, managing complicated cases, and offering specialized education. Hospital pharmacies act as primary access points for insulin delivery devices, especially for patients beginning treatment or moving to sophisticated devices like insulin pumps. However, home care settings are quickly becoming the largest and most vibrant segment of end users as China prioritizes the management of chronic diseases outside of hospital environments. With a greater focus on empowering patients, structured education, and self-management initiatives, more individuals are taking charge of their insulin therapy at home. Insulin pens are particularly common in these situations for both Type 2 and stable Type 1 patients due to their user-friendly nature and minimal training needed. The rise of online pharmacy services and digital health assistance tools further supports homecare adoption by increasing accessibility and providing remote support. Other end users, including long-term care facilities and community health services, represent a smaller but growing market segment. These entities often seek insulin delivery options that provide a balance of simplicity, safety, and reliability factors that make insulin pens the favored option in many instances.



"Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031
Aspects covered in this report
• Insulin Delivery Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By product Types
• Insulin Pens
• Insulin Pump
• Insulin Syringes
• Others Insulin Delivery Devices

By Disease Types
• Type 1
• Type 2

By End User
• Home care setting
• Hospitals & clinics
• Others End users “